Search Result

Results for "

CDK4/6 inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CDK (79) Apoptosis (13) Aurora Kinase (1) Bcl-2 Family (2) BMX Kinase (1) c-Met/HGFR (1) c-Myc (2) Carbonic Anhydrase (1) Caspase (1) Cytochrome P450 (1) Discoidin Domain Receptor (1) DNA/RNA Synthesis (1) Drug Metabolite (1) DYRK (1) EGFR (1) Epigenetic Reader Domain (2) Estrogen Receptor/ERR (2) FXR (2) HDAC (3) Histamine Receptor (1) Histone Acetyltransferase (1) Isotope-Labeled Compounds (1) Ligands for Target Protein for PROTAC (3) Mitochondrial Metabolism (1) MMP (2) Molecular Glues (2) NF-κB (1) p38 MAPK (1) PAK (1) PARP (2) PI3K (1) PROTACs (5) Raf (1) Reactive Oxygen Species (ROS) (4) Reference Standards (8) SARS-CoV (1) Ser/Thr Protease (1) Syk (2)
By Research Areas:	Cancer (85) Cardiovascular Disease (2) Infection (1) Inflammation/Immunology (3) Metabolic Disease (3) Neurological Disease (5)

By Targets:

CDK (79)

Apoptosis (13)

Aurora Kinase (1)

Bcl-2 Family (2)

BMX Kinase (1)

c-Met/HGFR (1)

c-Myc (2)

Carbonic Anhydrase (1)

Caspase (1)

Cytochrome P450 (1)

Discoidin Domain Receptor (1)

DNA/RNA Synthesis (1)

Drug Metabolite (1)

DYRK (1)

EGFR (1)

Epigenetic Reader Domain (2)

Estrogen Receptor/ERR (2)

FXR (2)

HDAC (3)

Histamine Receptor (1)

Histone Acetyltransferase (1)

Isotope-Labeled Compounds (1)

Ligands for Target Protein for PROTAC (3)

Mitochondrial Metabolism (1)

MMP (2)

Molecular Glues (2)

NF-κB (1)

p38 MAPK (1)

PAK (1)

PARP (2)

PI3K (1)

PROTACs (5)

Raf (1)

Reactive Oxygen Species (ROS) (4)

Reference Standards (8)

SARS-CoV (1)

Ser/Thr Protease (1)

Syk (2)

By Research Areas:

Cancer (85)

Cardiovascular Disease (2)

Infection (1)

Inflammation/Immunology (3)

Metabolic Disease (3)

Neurological Disease (5)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: CDK Serpin

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16297A

Abemaciclib Maximum Cited Publications 117 Publications Verification LY2835219	CDK	Neurological Disease Cancer
Abemaciclib (LY2835219) is a selective and BBB-permeable *CDK4/6* inhibitor with IC₅₀ values of 2 nM and 10 nM for CDK4 and CDK6, respectively.

HY-15777

Ribociclib 75+ Cited Publications LEE011	CDK	Neurological Disease Cancer
RRibociclib (LEE011) is an ATP-competitive and orally active CDK4/6 inhibitor that crosses the blood-brain barrier with IC₅₀ values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex .

HY-16297

Abemaciclib methanesulfonate Maximum Cited Publications 117 Publications Verification LY2835219 methanesulfonate	CDK	Cancer
Abemaciclib methanesulfonate (LY2835219 methanesulfonate) is a selective and BBB-permeable *CDK4/6* inhibitor with IC₅₀s of 2 nM and 10 nM for CDK4 and CDK6, respectively .

HY-15777A

Ribociclib hydrochloride 75+ Cited Publications LEE011 hydrochloride	CDK	Neurological Disease Cancer
RRibociclib (LEE011) hydrochloride is an ATP-competitive and orally active CDK4/6 inhibitor that crosses the blood-brain barrier with IC₅₀ values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex .

HY-101467

Trilaciclib 1 Publications Verification G1T28	CDK	Cancer
Trilaciclib (G1T28) is an orally active *CDK4/6* inhibitor with IC₅₀ values of 1 nM and 4 nM for CDK4 and CDK6, respectively. . Trilaciclib can effectively inhibit tumor cell proliferation and reduce the hematological toxicity caused by chemotherapy. Trilaciclib attenuates apoptosis and myelosuppression induced by 5FU (HY-90006) chemotherapy .

HY-15777B

Ribociclib succinate 75+ Cited Publications LEE011 succinate	CDK	Neurological Disease Cancer
RRibociclib (LEE011) succinate is an ATP-competitive and orally active CDK4/6 inhibitor that crosses the blood-brain barrier with IC₅₀ values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex .

HY-158106

AZD8421 1 Publications Verification	CDK	Cancer
AZD8421 is a selective CDK2 inhibitor (IC₅₀ = 9 nM) as well as achieving CDK family selectivity in cells versus key off-targets (CDK1, CDK4/6, CDK9), AZD8421 had no significant kinase inhibition outside the CDK family. AZD8421 inhibits cancer cell proliferation by inhibiting pRB phosphorylation, inducing cell cycle arrest in G1/S phase and senescence. AZD8421 can be studied in research for breast cancer and ovarian cancer .

HY-138946

XY028-140 1 Publications Verification	CDK PROTACs	Cancer
XY028-140 is a PROTAC connected by ligands for Cereblon and CDK. XY028-140 inhibits both CDK4/6 expression and CDK4/6 activity in cancer cells .

HY-112272

Lerociclib 2 Publications Verification G1T38	CDK	Cancer
Lerociclib (G1T38) is a potent and selective inhibitor of *CDK4/6, with IC₅₀s* of 1 nM, 2 nM for CDK4/CyclinD1 and CDK6/CyclinD3, respectively.

HY-162318

MYC degrader 1 1 Publications Verification	Molecular Glues c-Myc	Cancer
MYC degrader 1 (compound A80.2HCl) is an orally available MYC molecular glues degrader with anti-tumor activity. MYC degrader 1 restores pRB1 protein activity and re-establishes sensitivity of MYC overexpressing cancer cells to CDK4/6 inhibitors .

HY-16297AR

Abemaciclib (Standard) LY2835219 (Standard)	Reference Standards CDK	Cancer
Abemaciclib (Standard) is the analytical standard of Abemaciclib. This product is intended for research and analytical applications. Abemaciclib (LY2835219) is a selective and BBB-permeable *CDK4/6* inhibitor with IC₅₀ values of 2 nM and 10 nM for CDK4 and CDK6, respectively.

HY-112280

Crozbaciclib CDK4/6/1 Inhibitor	CDK	Cancer
Crozbaciclib (CDK4/6/1 Inhibitor) is a *CDK4/6* inhibitor with IC₅₀s of 3 and 1 nM, respectively.

HY-163786

PROTAC CDK4/6 degrader 1	PROTACs CDK Apoptosis	Cancer
PROTAC CDK4/6 degrader 1 is a CDK4/CDK6 PROTAC degrader, with DC₅₀ values of 10.5 nM and 2.5 nM, respectively. PROTAC CDK4/6 degrader 1 inhibits the proliferation of Jurkat cells (IC₅₀ = 0.18 μM), arrests the cell cycle at the G1 phase, and induces apoptosis. PROTAC CDK4/6 degrader 1 can be used for cancer research.

HY-142076

CDK4/6-IN-15	CDK	Cancer
CDK4/6-IN-15 is an orally active and selective *CDK4/6* inhibitor. CDK4/6-IN-15 potently inhibits cancer cells growth. CDK4/6-IN-15 arrests cell cycle at G1 phase and suppresses retinoblastoma tumour suppressor protein (Rb) phosphorylation at S780 and E2 factor (E2F)-regulated gene expression .

HY-16297AS

Abemaciclib-d8 LY2835219-d₈	CDK	Cancer
Abemaciclib-d₈ is the deuterium labeled Abemaciclib. Abemaciclib (LY2835219) is a selective CDK4/6 inhibitor with IC50 values of 2 nM and 10 nM for CDK4 and CDK6, respectively.

HY-N0805

Alisol B 23-acetate 3 Publications Verification 23-Acetylalismol B; 23-O-Acetylalisol B; Alisol B monoacetate	Apoptosis Reactive Oxygen Species (ROS) CDK MMP PARP FXR Syk	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Alisol B 23-acetate is an orally active prototerpane-type triterpenoid. Alisol B 23-acetate can be isolated from Alisma orientalis. Alisol B 23-acetate induces Apoptosis, promotes ROS generation, downregulates *CDK4/6, MMP-2/9, upregulates cleaved PARP, activates FXR* and inhibits Syk. Alisol B 23-acetate has anti-inflammatory and hepatoprotective activities. Alisol B 23-acetate protects the kidney from ischemia-reperfusion injury. Alisol B 23-acetate has anticancer activity against ovarian cancer, colon cancer, lung cancer, and gastric cancer. Alisol B 23-acetate can be used in the study of atherosclerosis and allergic asthma .

HY-101467A

Trilaciclib hydrochloride 1 Publications Verification G1T28 hydrochloride	CDK	Cancer
Trilaciclib (G1T28) hydrochloride is an orally active *CDK4/6* inhibitor with IC₅₀ values of 1 nM and 4 nM for CDK4 and CDK6, respectively. Trilaciclib hydrochloride can effectively inhibit tumor cell proliferation and reduce the hematological toxicity caused by chemotherapy. Trilaciclib hydrochloride attenuates apoptosis and myelosuppression induced by 5FU (HY-90006) chemotherapy .

HY-126534A

Abemaciclib metabolite M18 hydrochloride 2 Publications Verification LSN3106729 hydrochloride	Ligands for Target Protein for PROTAC CDK	Cancer
Abemaciclib metabolite M18 (LSN3106729) hydrochloride, the metabolite of Abemaciclib (HY-16297A), is a CDK inhibitor with antitumor activity. Abemaciclib metabolite M18 hydrochloride and a CRBN ligand have been used to design PROTAC CDK4/6 degrader .

HY-15777S

Ribociclib-d6 LEE011-d₆	CDK	Cancer
Ribociclib-d₆ (LEE011-d₆) is a deuterium labeled Ribociclib (HY-15777). Ribociclib is a highly specific CDK4/6 inhibitor with IC₅₀ values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex .

HY-126534

Abemaciclib metabolite M18 2 Publications Verification LSN3106729	Ligands for Target Protein for PROTAC CDK	Cancer
Abemaciclib metabolite M18 (LSN3106729), the metabolite of Abemaciclib (HY-16297A), is a CDK inhibitor with antitumor activity. Abemaciclib metabolite M18 and a CRBN ligand have been used to design PROTAC CDK4/6 degrader .

HY-136726

CGP-82996 CINK4	CDK	Cancer
GP-82996 (CINK4) is a pharmacological inhibitor of *CDK4/6. GP-82996 has IC₅₀s of 1.5, 5.6 and 25 μM for CDK4/cyclin* D1, CDK6/cyclin D1 and Cdk5/p35, respectively. GP-82996 induces the apoptosis of cancer cells U2OS. GP-82996 can be used in the research of cancer .

HY-15777C

Ribociclib succinate hydrate 75+ Cited Publications LEE011 succinate hydrate	CDK	Cancer
RRibociclib (LEE011) succinate hydrate is an ATP-competitive and orally active CDK4/6 inhibitor that crosses the blood-brain barrier with IC₅₀ values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex .

HY-15777R

Ribociclib (Standard) LEE011 (Standard)	Reference Standards CDK	Cancer
Ribociclib (Standard) is the analytical standard of Ribociclib. This product is intended for research and analytical applications. Ribociclib (LEE01) is a highly specific *CDK4/6* inhibitor with IC₅₀ values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex .

HY-129336

Abemaciclib metabolite M20 5 Publications Verification LSN3106726	CDK	Cancer
Abemaciclib metabolite M20 (LSN3106726), the active metabolite of Abemaciclib, is a selective *CDK4/6 inhibitor* for the treatment of cancer .

HY-137449

Rintodestrant G1T48	Estrogen Receptor/ERR CDK	Cancer
Rintodestrant (G1T48) is an orally active, non-steroidal and selective estrogen receptor degrader. Rintodestrant (G1T48) is also a *CDK4/6* inhibitor .

HY-114339

CDK4/6-IN-2	CDK	Cancer
CDK4/6-IN-2 is a potent *CDK4* and CDK6 inhibitor extracted from patent US20180000819A1, Compound 1, has IC₅₀s of 2.7 and 16 nM for CDK4 and CDK6, respectively .

HY-15777AS

Ribociclib-d6 hydrochloride LEE011-d₆ hydrochloride	Isotope-Labeled Compounds CDK	Cancer
Ribociclib-d₆ (LEE011-d₆) hydrochloride is a deuterium labeled Ribociclib. Ribociclib is a highly specific CDK4/6 inhibitor with IC₅₀ values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex .

HY-146213

CDK4/6-IN-12	CDK	Cancer
CDK4/6-IN-12 is a potent cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. CDK4/6-IN-12 has enzymatic inhibitory activity for CDK4 and CDK6 with IC₅₀ of 592.3 nM and 3090 nM, respectively. CDK4/6-IN-12 can be used for the research of cancer .

HY-153894

SRX3177	CDK Epigenetic Reader Domain PI3K NF-κB SARS-CoV	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
SRX3177 is a triple inhibitor of *CDK4/6, PI3K, and BRD4, with IC₅₀s of <2.5 nM (CDK4), 3.3 nM (CDK6), 33 nM (BRD4 BD1), 89 nM (BRD4 BD2), 79 nM (PI3Kα), 83 nM (PI3Kδ), 3.18 μM (PI3Kγ) , respectively. SRX3177 blocks the interaction between the SARS-CoV-2 E protein* and the BRD2/4 BD1 domain, restores E protein-attenuated NF-κB activity. SRX3177 exerts broad cytotoxic activity against cancer cells. SRX3177 can be used for the study of anti-SARS-CoV-2 and cancer .

HY-169947

DDO-6079	CDK	Cancer
DDO-6079 is a potent CDC37 inhibitor. DDO-6079 inhibits HSP90-CDC37 and CDC37-CDK4/6 chaperone complex by binding to an allosteric site on CDC37. DDO-6079 decreases the thermostability of CDK6 .

HY-171459

LEQ803 N-Desmethyl Ribociclib	Drug Metabolite Cytochrome P450	Cancer
LEQ803 (N-Desmethyl Ribociclib) is a drug metabolite of the CDK4/6 inhibitor Ribociclib (HY-15777), which is produced through metabolism by CYP3A4. LEQ803 has potential application value in the field of oncology .

HY-162318A

MYC degrader 1 TFA 1 Publications Verification	Molecular Glues c-Myc	Cancer
MYC degrader 1 TFA (compound A80.2HCl) is an orally available MYC molecular glues degrader with anti-tumor activity. MYC degrader 1 TFA restores pRB1 protein activity and re-establishes sensitivity of MYC overexpressing cancer cells to CDK4/6 inhibitors .

HY-115992

CDK4/6-IN-9	CDK	Cancer
CDK4/6-IN-9 (compound 10) is a selective *CDK4/6* inhibitor with an IC₅₀ of 905 nM for CDK6/cyclin D1. CDK4/6-IN-9 has the potential for multiple myeloma (MM) research .

HY-142076A

CDK4/6-IN-15 hydrochloride	CDK	Cancer
CDK4/6-IN-15 hydrochloride is an orally active and selective *CDK4/6* inhibitor. CDK4/6-IN-15 hydrochloride potently inhibits cancer cells growth. CDK4/6-IN-15 hydrochloride arrests cell cycle at G1 phase and suppresses retinoblastoma tumour suppressor protein (Rb) phosphorylation at S780 and E2 factor (E2F)-regulated gene expression .

HY-153336

PRT3645	CDK	Cancer
PRT3645 (Example 20) is a CDK Inhibitor. CDK-IN-12 Inhibits CDK4/6 with IC₅₀ values less than 20 nM .

HY-153088

CDK4/6-IN-16	CDK	Cancer
CDK4/6-IN-16 (example 195) is a potent *CDK4* and CDK6 inhibitor, with an IC₅₀ of 0.013 μM for *CDK4. CDK4/6-IN-16 can be used for the research of CDK4-mediated* disorders, such as cancer .

HY-129336S

Abemaciclib metabolite M20-d8 LSN3106726-d₈	CDK	Cancer
Abemaciclib metabolite M20-d₈ is the deuterium labeled Abemaciclib metabolite M20. Abemaciclib metabolite M20 (LSN3106726), the active metabolite of Abemaciclib, is a selective CDK4/6 inhibitor .

HY-15777S1

Ribociclib-d8 LEE011-d₈	CDK	Cancer
Ribociclib-d₈ is the deuterium labeled Ribociclib . Ribociclib (LEE01) is a highly specific CDK4/6 inhibitor with IC₅₀ values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex .

HY-151898

CDK4/6-IN-14	CDK	Cancer
CDK4/6-IN-14 is a potent and highly selective *CDK4* and CDK6 (CDK) inhibitor with IC₅₀s of 10 nM and 16 nM, respectively. CDK4/6-IN-14 exhibits more than 60-fold selectivity over CDKs 1, 2, 7, and 9, and shows high selectivity among other 205 kinases .

HY-15777AR

Ribociclib hydrochloride (Standard) LEE011 hydrochloride (Standard)	Reference Standards CDK	Cancer
Ribociclib (Standard) (LEE011(Standard)) hydrochloride is the analytical standard of Ribociclib hydrochloride (HY-15777A). This product is intended for research and analytical applications. Ribociclib hydrochloride (LEE011 hydrochloride) is a highly specific *CDK4/6* inhibitor with IC₅₀ values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex.

HY-146214

CDK4/6-IN-13	CDK	Cancer
As a cdk4/6 inhibitor. Compounds 10B and 10C showed low nanomolar activity, ideal antiproliferative activity, excellent metabolic properties and acceptable pharmacokinetics on cdk4/6.

HY-168996

LA-CB1	CDK Apoptosis	Cancer
LA-CB1 is an Abemaciclib (HY-16297A) derivative that targets *CDK4/6* and promotes its degradation via the ubiquitin-proteasome pathway, thereby disrupting the CDK4/6-Cyclin D1-Rb-E2F axis and inducing G0/G1 cell cycle arrest and apoptosis. LA-CB1 exhibits antiproliferative activity against MDA-MB-231 cells, with an IC₅₀ of 0.27 µM, and effectively inhibits epithelial-mesenchymal transition (EMT), cell migration, invasion, and angiogenesis. In highly aggressive models such as triple-negative breast cancer (TNBC), LA-CB1 significantly suppresses tumor growth in a dose-dependent manner. LA-CB1 holds potential for research in the field of breast cancer .

HY-134303

CST651 PROTAC CDK4/6 degrader 34	PROTACs CDK	Cancer
CST651 (PROTAC CDK4/6 degrader 34) is a selective *cyclin dependent kinase CDK4/6* PROTAC** degrader. CST651 can degrade CDK4 and CDK6 in MM.1S cells with DC₅₀ values of 20 and 5.1 nM. CST651 can inhibit cancer cells proliferation and migration. CST651 can be used for the research of cancer, such as acute lymphoblastic leukemia . (Structure Note: Pink: CDK4/6 ligand (HY-50767); Blue: VHL ligand (HY-125905); Black: linker (HY-W017440))

HY-155736

MAPK-IN-2	p38 MAPK EGFR Raf CDK c-Met/HGFR	Cancer
MAPK-IN-2 (compound 3h) is a potent MAPK inhibitor with antineoplastic activity. MAPK-IN-2 inhibits cancer cell proliferation among serval cancer cell lines, and suppresses MAPK pathway with potant efficacy (EGFR ^WT IC₅₀=281 nM, c-MET IC₅₀=205 nM, B-RAF ^WT IC₅₀=112 nM, and CDK4/6 IC₅₀=95 and 184 nM, respectively). MAPK-IN-2 even shows a remarkable potency against mutated EGFR and B-RAF (EGFR ^T790M IC₅₀=69 nM and B-RAF ^V600E IC₅₀=83 nM) .

HY-16297R

Abemaciclib methanesulfonate (Standard) LY2835219 methanesulfonate (Standard)	Reference Standards CDK	Cancer
Abemaciclib (methanesulfonate) (Standard) is the analytical standard of Abemaciclib (methanesulfonate). This product is intended for research and analytical applications. Abemaciclib methanesulfonate (LY2835219 methanesulfonate) is a selective CDK4/6 inhibitor with IC50s of 2 nM and 10 nM for CDK4 and CDK6, respectively .

HY-178516

PROTAC CDK4/6/9 degrader 2	CDK PROTACs	Cancer
PROTAC CDK4/6/9 degrader 2 (Compound P4) is a CDK4/6/9 PROTAC prodrug with oral activity and low toxicity. PROTAC CDK4/6/9 degrader 2 can significantly inhibit tumor growth and suppress tumor lung metastasis. PROTAC CDK4/6/9 degrader 2 can be used in the research of cancer such as breast cancer. (Pink: CDK4/6/9 Ligand (HY-168440); Blue: CRBN Ligand (HY-178517); Black: Linker (HY-178512))

HY-178452

PROTAC CDK4/6/9 degrader 1	PROTACs CDK Apoptosis	Cancer
PROTAC CDK4/6/9 degrader 1 is a *CDK4/6/9* PROTAC degrader. PROTAC CDK4/6/9 degrader 1 degrades *CDK4, CDK6, and CDK9* in TNBC cells and inhibits TNBC cell proliferation. PROTAC CDK4/6/9 degrader 1 induces G1 phase arrest, promotes apoptosis, and suppresses cell migration and invasion in TNBC cells. PROTAC CDK4/6/9 degrader 1 can be used for the study of triple-negative breast cancer (TNBC). (Pink: CDK4/6/9 ligand (HY-168440), Blue: CRBN Ligand (HY-14658), Black: Linker (HY-178512), E3 ligase ligand-linker conjugate (HY-178515)) .

HY-112418

CDK4/6-IN-18	CDK	Cancer
CDK4/6-IN-18 (Example 2BrIC) is a selective *CDK4/6* inhibitor. CDK4/6-IN-18 inhibits ionizing radiation (IR)-induced DNA damage in cells .

HY-108420

INK4C-IN-2 1 Publications Verification	CDK	Cancer
INK4C-IN-2 is a p18 ^INK4C inhibitor. NK4C-IN-2 promotes hematopoietic stem cells (HSCs) division by inhibiting INK4C and activating *CDK4/6, with an ED₅₀* of 5.21 nM. INK4C-IN-2 shows no cytotoxic to normal 32D cells, HSCs, leukemia cell lines and myeloma cell lines .

HY-174088

CDK4/6/BRD4-IN-2	CDK Discoidin Domain Receptor Apoptosis Reactive Oxygen Species (ROS) DNA/RNA Synthesis	Cancer
CDK4/6/BRD4-IN-2 (Compound PJ2) is a dual inhibitor of *CDK4/6* and BRD4 with IC₅₀ values for *CDK4, CDK6, BRD4 (BD1), and BRD4 (BD2)* of 168.75, 292.45, 23.17, and 3.12 nM respectively. CDK4/6/BRD4-IN-2 has a strong inhibitory effect on non-small cell lung cancer (NSCLC) cell lines. CDK4/6/BRD4-IN-2 induces cell cycle arrest, senescence and apoptosis through ROS-mediated DNA damage. CDK4/6/BRD4-IN-2 can also effectively inhibit the migration and invasion of NCI-H358 cells. CDK4/6-IN-2 can be used for the study of KRAS-mutated NSCLC .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0805

Alisol B 23-acetate 3 Publications Verification 23-Acetylalismol B; 23-O-Acetylalisol B; Alisol B monoacetate	Triterpenes Alisma plantago-aquatica Linn. Classification of Application Fields Terpenoids Other Diseases Alismataceae Plants Disease Research Fields Source Classification	Apoptosis Reactive Oxygen Species (ROS) CDK MMP PARP FXR Syk
Alisol B 23-acetate is an orally active prototerpane-type triterpenoid. Alisol B 23-acetate can be isolated from Alisma orientalis. Alisol B 23-acetate induces Apoptosis, promotes ROS generation, downregulates *CDK4/6, MMP-2/9, upregulates cleaved PARP, activates FXR* and inhibits Syk. Alisol B 23-acetate has anti-inflammatory and hepatoprotective activities. Alisol B 23-acetate protects the kidney from ischemia-reperfusion injury. Alisol B 23-acetate has anticancer activity against ovarian cancer, colon cancer, lung cancer, and gastric cancer. Alisol B 23-acetate can be used in the study of atherosclerosis and allergic asthma .

HY-N0805R

Alisol B 23-acetate (Standard) 23-Acetylalismol B (Standard); 23-O-Acetylalisol B (Standard); Alisol B monoacetate (Standard)	Triterpenes Structural Classification Alisma plantago-aquatica Linn. Terpenoids Alismataceae Plants Source Classification	Reference Standards Apoptosis Reactive Oxygen Species (ROS) CDK MMP PARP FXR Syk
Alisol B 23-acetate (Standard) is the analytical standard of Alisol B 23-acetate (HY-N0805). This product is intended for research and analytical applications. Alisol B 23-acetate is an orally active prototerpane-type triterpenoid. Alisol B 23-acetate can be isolated from Alisma orientalis. Alisol B 23-acetate induces Apoptosis, promotes ROS generation, downregulates *CDK4/6, MMP-2/9, upregulates cleaved PARP, activates FXR* and inhibits Syk. Alisol B 23-acetate has anti-inflammatory and hepatoprotective activities. Alisol B 23-acetate protects the kidney from ischemia-reperfusion injury. Alisol B 23-acetate has anticancer activity against ovarian cancer, colon cancer, lung cancer, and gastric cancer. Alisol B 23-acetate can be used in the study of atherosclerosis and allergic asthma .

Cat. No.	Product Name	Chemical Structure

HY-16297AS

Abemaciclib-d8
Abemaciclib-d₈ is the deuterium labeled Abemaciclib. Abemaciclib (LY2835219) is a selective CDK4/6 inhibitor with IC50 values of 2 nM and 10 nM for CDK4 and CDK6, respectively.

HY-15777S

Ribociclib-d6
Ribociclib-d₆ (LEE011-d₆) is a deuterium labeled Ribociclib (HY-15777). Ribociclib is a highly specific CDK4/6 inhibitor with IC₅₀ values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex .

HY-15777AS

Ribociclib-d6 hydrochloride
Ribociclib-d₆ (LEE011-d₆) hydrochloride is a deuterium labeled Ribociclib. Ribociclib is a highly specific CDK4/6 inhibitor with IC₅₀ values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex .

HY-129336S

Abemaciclib metabolite M20-d8
Abemaciclib metabolite M20-d₈ is the deuterium labeled Abemaciclib metabolite M20. Abemaciclib metabolite M20 (LSN3106726), the active metabolite of Abemaciclib, is a selective CDK4/6 inhibitor .

HY-15777S1

Ribociclib-d8
Ribociclib-d₈ is the deuterium labeled Ribociclib . Ribociclib (LEE01) is a highly specific CDK4/6 inhibitor with IC₅₀ values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex .

HY-126534S

Abemaciclib metabolite M18-d8
Abemaciclib metabolite M18-d₈ is the deuterium labeled Abemaciclib metabolite M18. Abemaciclib metabolite M18 (LSN3106729), the metabolite of Abemaciclib (HY-16297A), is a CDK inhibitor with antitumor activity. Abemaciclib metabolite M18 and a CRBN ligand have been used to design PROTAC CDK4/6 degrader .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks